JPMorgan Chase & Co. lowered its holdings in shares of InMode Ltd. by 12.3% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,038,603 shares of the healthcare company's stock after selling 145,448 shares during the period. JPMorgan Chase & Co. owned about 1.24% of InMode worth $17,604,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Renaissance Technologies LLC lifted its stake in InMode by 11.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,068,396 shares of the healthcare company's stock valued at $37,728,000 after acquiring an additional 214,200 shares in the last quarter. State Street Corp boosted its position in shares of InMode by 3.7% in the third quarter. State Street Corp now owns 2,044,640 shares of the healthcare company's stock valued at $34,657,000 after acquiring an additional 73,183 shares during the period. Doma Perpetual Capital Management LLC grew its position in shares of InMode by 210.7% during the 2nd quarter. Doma Perpetual Capital Management LLC now owns 2,011,240 shares of the healthcare company's stock valued at $36,685,000 after purchasing an additional 1,363,841 shares in the last quarter. Federated Hermes Inc. grew its position in InMode by 191.9% during the second quarter. Federated Hermes Inc. now owns 1,125,017 shares of the healthcare company's stock worth $20,520,000 after buying an additional 739,629 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in InMode by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,101,951 shares of the healthcare company's stock valued at $18,678,000 after purchasing an additional 6,282 shares in the last quarter. 68.04% of the stock is currently owned by institutional investors.

InMode traded down 0.7% during mid-day trading on Friday, hitting $15.90. The stock had a trading volume of 1,237,080 shares, compared to its average volume of 1,013,985. The firm has a market capitalization of $1.34 billion, a P/E ratio of 8.59 and a beta of 2.12. The firm's 50 day moving average is $18.06 and its 200 day moving average is $17.30. InMode Ltd. has a one year low of $14.87 and a one year high of $26.80.

Several analysts have issued reports on INMD shares. BTIG Research initiated coverage on InMode in a research note on Thursday, October 17th. They issued a "buy" rating and a $25.00 target price for the company. Needham & Company LLC reiterated a "hold" rating on shares of InMode in a research note on Thursday, October 31st. Finally, Barclays decreased their target price on shares of InMode from $27.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $22.40.

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.

JPMorgan Chase & Co. Sells 145,448 Shares of InMode Ltd. (NASDAQ:INMD)

JPMorgan Chase & Co. reduced its holdings in InMode Ltd. by 12.3% during the third quarter. Other institutional investors, including Renaissance Technologies LLC, State Street Corp, Doma Perpetual Capital Management LLC, Federated Hermes Inc., and Geode Capital Management LLC, also adjusted their stakes in InMode. Analysts from BTIG Research, Needham & Company LLC, and Barclays provided recommendations and target prices for InMode's stock. InMode designs minimally invasive aesthetic medical products and has a market capitalization of $1.34 billion.